Skip to content
For laboratory research use only. Not for human or veterinary use. Nothing here is medical advice.
123GLP-123 Research Library

Retatrutide vs tirzepatide vs semaglutide

The three most-studied incretin peptides, side by side: what each one targets, its molecular data, how long it lasts and how to store it.

In short: semaglutide activates one receptor (GLP-1), tirzepatide two (GLP-1 and GIP) and retatrutide three (GLP-1, GIP and glucagon). All three are once-weekly, albumin-binding peptides with half-lives of roughly 5–7 days. Tirzepatide and semaglutide are approved medicines; retatrutide is still in phase 3 trials.

Comparison of retatrutide, tirzepatide and semaglutide
RetatrutideTirzepatideSemaglutide
Receptors targetedGLP-1, GIP and glucagon (triple agonist)GLP-1 and GIP (dual agonist)GLP-1 only
Research name at GLP-123GLP-3 RTGLP-2 TZGLP-1 SG
Peptide length39 amino acids39 amino acids31 amino acids
Molecular formulaC221H342N46O68C225H348N48O68C187H291N45O59
Molecular weight≈ 4,731 g/mol≈ 4,813 g/mol≈ 4,114 g/mol
CAS number2381089-83-22023788-19-2910463-68-2
Half-life extensionFatty diacid (C20) side chain, albumin bindingFatty diacid (C20) side chain, albumin bindingFatty diacid (C18) side chain, albumin binding
Reported elimination half-life≈ 6 days≈ 5 days≈ 7 days
Regulatory status (2026)Investigational, phase 3 (TRIUMPH program)Approved (Mounjaro 2022, Zepbound 2023)Approved (Ozempic 2017, Wegovy 2021, oral Rybelsus 2019)
Landmark trialPhase 2 obesity trial (NEJM 2023)SURMOUNT-1 (NEJM 2022)STEP 1 (NEJM 2021)
Lyophilized storage−20 °C long term, protected from light−20 °C long term, protected from light−20 °C long term, protected from light
After reconstitution2–8 °C, use within the window your protocol validates2–8 °C, use within the window your protocol validates2–8 °C, use within the window your protocol validates
GLP-123 batches tested6 batches, avg purity 99.68%12 batches, avg purity 99.71%3 batches, avg purity 99.87%

Questions researchers ask

What is the main difference between retatrutide, tirzepatide and semaglutide?

The number of receptors each one activates. Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds the glucagon receptor, making it a triple agonist.

Which has the longest half-life?

Semaglutide, at about 7 days, followed by retatrutide (about 6 days) and tirzepatide (about 5 days). All three use a fatty-acid side chain that binds albumin to slow clearance.

Is retatrutide approved?

No. As of 2026 retatrutide is investigational and in phase 3 trials. Tirzepatide and semaglutide are approved medicines. Research-grade versions of all three are for laboratory use only.

How should these peptides be stored for research?

Lyophilized powder is typically kept at −20 °C, protected from light. Once reconstituted, keep vials at 2–8 °C and use them within the stability window your protocol has validated.

Sources

  1. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389:514-526.
  2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216.
  3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
  4. PubChem compound records: retatrutide, tirzepatide, semaglutide (formula, molecular weight, CAS).

Half-life values are reported human pharmacokinetic figures from published studies, given for context. Research-grade peptides from GLP-123 are for laboratory use only.